American Century Companies Inc. Buys 515,090 Shares of Pacira BioSciences, Inc. $PCRX

American Century Companies Inc. boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 77.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,182,513 shares of the company’s stock after buying an additional 515,090 shares during the quarter. American Century Companies Inc.’s holdings in Pacira BioSciences were worth $28,262,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Pacira BioSciences in the 1st quarter valued at about $51,000. US Bancorp DE lifted its holdings in Pacira BioSciences by 31.0% during the first quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after acquiring an additional 537 shares in the last quarter. Brooklyn Investment Group grew its stake in Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock valued at $56,000 after acquiring an additional 1,764 shares during the period. Strs Ohio acquired a new position in Pacira BioSciences in the first quarter valued at about $75,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Pacira BioSciences by 17.8% in the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock worth $84,000 after acquiring an additional 531 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Buying and Selling at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,960 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $24.09, for a total transaction of $95,396.40. Following the sale, the insider owned 178,367 shares in the company, valued at $4,296,861.03. This represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Trading Down 1.0%

Pacira BioSciences stock opened at $23.57 on Monday. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.48 and a beta of 0.36. The firm has a 50-day moving average of $23.32 and a 200-day moving average of $24.22. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. Pacira BioSciences, Inc. has a one year low of $16.41 and a one year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $179.52 million for the quarter, compared to the consensus estimate of $182.86 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. Pacira BioSciences’s quarterly revenue was up 6.5% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, equities analysts expect that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PCRX. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Monday, November 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, November 24th. Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Truist Financial reduced their target price on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $27.60.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.